Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1979 1
1981 1
1985 1
1986 1
1987 3
1988 2
1990 2
1991 4
1992 3
1993 4
1994 5
1995 5
1996 1
1997 5
1998 1
1999 5
2000 12
2001 12
2002 9
2003 6
2004 9
2005 4
2006 3
2007 3
2008 1
2009 1
2010 3
2011 2
2012 1
2013 3
2014 7
2015 7
2016 3
2018 2
2019 2
2020 1
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Among authors: weidmann e. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Stewart AK, et al. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. N Engl J Med. 2015. PMID: 25482145 Free article. Clinical Trial.
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B, Federico M, Caballero D, Dearden C, Morschhauser F, Jäger U, Trümper L, Zucca E, Gomes da Silva M, Pettengell R, Weidmann E, d'Amore F, Tilly H, Zinzani PL. Coiffier B, et al. Among authors: weidmann e. Cancer Treat Rev. 2014 Oct;40(9):1080-8. doi: 10.1016/j.ctrv.2014.08.001. Epub 2014 Aug 24. Cancer Treat Rev. 2014. PMID: 25199959 Free article. Review.
Dual TCR-expressing T lymphocytes in health and disease.
Hinz T, Weidmann E, Kabelitz D. Hinz T, et al. Among authors: weidmann e. Int Arch Allergy Immunol. 2001 May;125(1):16-20. doi: 10.1159/000053792. Int Arch Allergy Immunol. 2001. PMID: 11385284 Review.
Wilms tumor gene expression in acute myeloid leukemias.
Bergmann L, Maurer U, Weidmann E. Bergmann L, et al. Among authors: weidmann e. Leuk Lymphoma. 1997 May;25(5-6):435-43. doi: 10.3109/10428199709039030. Leuk Lymphoma. 1997. PMID: 9250813 Review.
128 results